Anti-CFL2 monoclonal antibody

Pre-made anti-CFL2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CFL2/CFL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2425-Ab-1/ GM-Tg-hg-IP2425-Ab-2Anti-Human CFL2 monoclonal antibodyHuman
GM-Tg-rg-IP2425-Ab-1/ GM-Tg-rg-IP2425-Ab-2Anti-Rat CFL2 monoclonal antibodyRat
GM-Tg-mg-IP2425-Ab-1/ GM-Tg-mg-IP2425-Ab-2Anti-Mouse CFL2 monoclonal antibodyMouse
GM-Tg-cynog-IP2425-Ab-1/ GM-Tg-cynog-IP2425-Ab-2Anti-Cynomolgus/ Rhesus macaque CFL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2425-Ab-1/ GM-Tg-felg-IP2425-Ab-2Anti-Feline CFL2 monoclonal antibodyFeline
GM-Tg-cang-IP2425-Ab-1/ GM-Tg-cang-IP2425-Ab-2Anti-Canine CFL2 monoclonal antibodyCanine
GM-Tg-bovg-IP2425-Ab-1/ GM-Tg-bovg-IP2425-Ab-2Anti-Bovine CFL2 monoclonal antibodyBovine
GM-Tg-equg-IP2425-Ab-1/ GM-Tg-equg-IP2425-Ab-2Anti-Equine CFL2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2425-Ab-1/ GM-Tg-hg-IP2425-Ab-2; GM-Tg-rg-IP2425-Ab-1/ GM-Tg-rg-IP2425-Ab-2;
GM-Tg-mg-IP2425-Ab-1/ GM-Tg-mg-IP2425-Ab-2; GM-Tg-cynog-IP2425-Ab-1/ GM-Tg-cynog-IP2425-Ab-2;
GM-Tg-felg-IP2425-Ab-1/ GM-Tg-felg-IP2425-Ab-2; GM-Tg-cang-IP2425-Ab-1/ GM-Tg-cang-IP2425-Ab-2;
GM-Tg-bovg-IP2425-Ab-1/ GM-Tg-bovg-IP2425-Ab-2; GM-Tg-equg-IP2425-Ab-1/ GM-Tg-equg-IP2425-Ab-2
Products NameAnti-CFL2 monoclonal antibody
Formatmab
Target NameCFL2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CFL2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2425-Ag-1Recombinant multi-species COF2/ CFL2/ NEM7 protein


    Target information

    Target IDGM-IP2425
    Target NameCFL2
    Gene ID1073,12632,366624,693875,490649,101083089,539332,100050494
    Gene Symbol and SynonymsCFL2,cofilin-2,NEM7
    Uniprot AccessionQ9Y281,Q148F1
    Uniprot Entry NameCOF2_HUMAN,COF2_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000165410
    Target ClassificationN/A

    The target: CFL2, gene name: CFL2, also named as NEM7. This gene encodes an intracellular protein that is involved in the regulation of actin-filament dynamics. This protein is a major component of intranuclear and cytoplasmic actin rods. It can bind G- and F-actin in a 1:1 ratio of cofilin to actin, and it reversibly controls actin polymerization and depolymerization in a pH-dependent manner. Mutations in this gene cause nemaline myopathy type 7, a form of congenital myopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.